시장보고서

상품코드

1654322

상피종 치료제 시장 규모, 점유율, 동향 분석 보고서 : 종류별, 약물 종류별, 유통 채널별, 지역별, 부문별 예측(2025-2030년)

Epithelioma Treatment Market Size, Share & Trends Analysis Report By Type, By Drug Class (Hedgehog Pathway Inhibitors, Immune Checkpoint Inhibitors), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

발행일: 2025년 01월 | 리서치사:

Grand View Research | 페이지 정보: 영문 100 Pages | 배송안내 : 2-10일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

상피종 치료제 시장 성장과 동향:

Grand View Research, Inc.의 최신 보고서에 따르면, 세계 상피종 치료제 시장 규모는 2025년부터 2030년까지 연평균 10.4%의 CAGR을 기록하여 2030년에는 97억 3,000만 달러에 달할 것으로 예상됩니다.

피부암, 특히 기저세포암(BCC)과 편평상피암(SCC)의 발병률 증가가 시장 확대의 주요 요인입니다. 미국 암협회에 따르면, 미국에서는 2024년 약 100,640명의 신규 흑색종 환자가 발생할 것으로 예상되며, 그 중 남성은 약 59,170명, 여성은 약 41,470명입니다. 또한, 남성 5,430명, 여성 2,860명 등 약 8,290명이 사망할 것으로 예측됩니다. 이러한 유병률 증가는 첨단 치료에 대한 수요 증가를 뒷받침하며 시장 성장에 크게 기여하고 있습니다.

의료기술의 발전도 중요한 역할을 하고 있습니다. 면역관문억제제(예: 펨브롤리주맙, 니볼루맙)와 표적 치료제(예: BCC에 대한 비스모데지브)와 같은 혁신적인 치료법의 개발은 치료 옵션을 변화시키고, 환자들에게 새로운 희망을 주며, 시장 기회를 확대하고 있습니다. 이러한 발전은 이러한 치료의 효과와 안전성을 강조하는 우수한 임상시험 결과와 FDA 승인에 의해 뒷받침되고 있습니다.

규제 기관과 정부의 노력도 시장 형성에 매우 중요합니다. 미국에서는 유망한 치료법에 대한 FDA의 조기 승인 절차가 새로운 치료법에 대한 신속한 접근을 촉진하고 있습니다. 또한 유럽에서는 유럽의약품청(EMA)과 같은 이니셔티브가 신약 개발 및 승인에 중요한 지원을 하고 있습니다. 정부의 암 연구 자금 지원과 대중의 인식 개선 캠페인은 조기 발견과 조기 치료를 강화하여 시장 성장을 더욱 촉진하고 있습니다.

상피종 치료제 시장 : 분석 개요

유형별로는 기저세포상피종이 2024년 61.0%의 점유율을 차지하며 시장을 주도했습니다. 기저세포상피종의 일종인 BCC는 전 세계적으로 가장 흔한 피부암입니다.
약물군별로는 헤지혹 경로 억제제가 2024년 41.2% 이상의 최대 매출 점유율을 차지했습니다. 이러한 우위는 BCC 치료에서 이러한 억제제의 효과, 피부암 발생률 증가, 최근 약물 개발의 괄목할 만한 진전에 기인합니다.
판매 채널별로는 병원 약국 부문이 2024년 시장을 주도하며 51.8% 이상의 높은 매출 점유율을 차지했습니다.
북미 상피종 치료제 시장은 2024년 37.5%의 매출 점유율로 세계 시장을 장악했으며, 이는 주로 피부암의 높은 발병률과 탄탄한 의료 인프라가 그 원동력이 되었습니다.

시장 점유율 : 지역별(2024년·2030년)
시장 대시보드 : 지역별
시장 규모 예측과 동향 분석(2018-2030년)
북미
- 국가별(2018-2030년)
- 미국
- 캐나다
- 멕시코
유럽
- 국가별(2018-2030년)
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 노르웨이
- 덴마크
- 스웨덴
아시아태평양
- 국가별(2018-2030년)
- 일본
- 중국
- 인도
- 한국
- 호주
- 태국
라틴아메리카
- 국가별(2018-2030년)
- 브라질
- 아르헨티나
중동 및 아프리카
- 국가별(2018-2030년)
- 남아프리카공화국
- 사우디아라비아
- 아랍에미리트
- 쿠웨이트

제8장 경쟁 구도

진출 기업 개요
기업의 시장 포지션 분석
기업 분류
전략 매핑
기업 개요/상장 기업
- Bristol-Myers Squibb Company
- Merck &Co., Inc.
- Novartis AG
- Amgen Inc.
- Pfizer Inc.
- Sanofi
- Johnson & Johnson Services, Inc.
- F. Hoffmann-La Roche Ltd

ksm 25.03.17

Epithelioma Treatment Market Growth & Trends:

The global epithelioma treatment market size is expected to reach USD 9.73 billion by 2030, registering a CAGR of 10.4% from 2025 to 2030, according to a new report by Grand View Research, Inc. The growing incidence of skin cancers, notably basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), is a major driver of market expansion. According to the American Cancer Society, the U.S. is expected to see approximately 100,640 new cases of melanoma in 2024, with around 59,170 in men and 41,470 in women. Additionally, melanoma is anticipated to cause about 8,290 deaths, including 5,430 men and 2,860 women. This escalating prevalence underscores the increasing demand for advanced treatments and contributes significantly to the market's growth.

Advancements in medical technology also play a crucial role. The development of innovative therapies, such as immune checkpoint inhibitors (e.g., pembrolizumab and nivolumab) and targeted therapies (e.g., vismodegib for BCC), has revolutionized treatment options, offering new hope for patients and expanding market opportunities. These advancements are further supported by positive clinical trial results and FDA approvals, which underscore the efficacy and safety of these treatments.

Regulatory bodies and government initiatives are also pivotal in shaping the market. In the U.S., the FDA's accelerated approval process for promising treatments facilitates faster access to new therapies. Additionally, initiatives like the European Medicines Agency (EMA) provide crucial support in developing and approving new drugs in Europe. Government funding for cancer research and public awareness campaigns are enhancing early detection and treatment, further driving market growth.

Epithelioma Treatment Market Report Highlights:

Based on type, basal cell epithelioma dominated the market and accounted for a share of 61.0% in 2024. BCC, a type of basal cell epithelioma, is the most common form of skin cancer globally.
Based on drug class, the hedgehog pathway inhibitors segment secured the largest revenue share of over 41.2% in 2024. This prominence is attributed to the efficacy of these inhibitors in treating BCC, the increasing incidence of skin cancers, and significant recent advancements in drug development.
Based on distribution channel, The hospital pharmacies segment led the market in 2024, capturing a substantial revenue share of over 51.8%.
North America epithelioma treatment market dominated the global market with a revenue share of 37.5% in 2024, largely fueled by the high incidence of skin cancers and a well-established healthcare infrastructure.

Chapter 1. Methodology and Scope

1.1. Market Segmentation & Scope
1.2. Segment Definitions
- 1.2.1. Type
- 1.2.2. Drug Class
- 1.2.3. Distribution Channel
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
- 1.5.1. Purchased Database
- 1.5.2. GVR's Internal Database
- 1.5.3. Secondary Sources
- 1.5.4. Primary Research
1.6. Information Analysis
- 1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
- 1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives

Chapter 2. Executive Summary

2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot

Chapter 3. Epithelioma Treatment Market Variables, Trends, & Scope

3.1. Market Lineage Outlook
3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
- 3.3.1. Industry Analysis - Porter's Five Forces Analysis
  - 3.3.1.1. Supplier Power
  - 3.3.1.2. Buyer Power
  - 3.3.1.3. Substitution Threat
  - 3.3.1.4. Threat of New Entrants
  - 3.3.1.5. Competitive Rivalry
- 3.3.2. PESTLE Analysis

Chapter 4. Epithelioma Treatment Market: Type Business Analysis

4.1. Type Market Share, 2024 & 2030
4.2. Type Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Million)
4.4. Basal Cell Epithelioma
- 4.4.1. Basal Cell Epithelioma Market, 2018 - 2030 (USD Million)
4.5. Squamous Cell Epithelioma
- 4.5.1. Squamous Cell Epithelioma Market, 2018 - 2030 (USD Million)
4.6. Others
- 4.6.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Epithelioma Treatment Market: Drug Class Business Analysis

5.1. Drug Class Market Share, 2024 & 2030
5.2. Drug Class Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
5.4. Hedgehog Pathway Inhibitors
- 5.4.1. Hedgehog Pathway Inhibitors Market, 2018 - 2030 (USD Million)
5.5. Immune Checkpoint Inhibitors
- 5.5.1. Immune Checkpoint Inhibitors Market, 2018 - 2030 (USD Million)
5.6. Chemotherapeutic Agents
- 5.6.1. Chemotherapeutic Agents Market, 2018 - 2030 (USD Million)
5.7. Others
- 5.7.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. Epithelioma Treatment Market: Distribution Channel Business Analysis

6.1. Distribution Channel Market Share, 2024 & 2030
6.2. Distribution Channel Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
6.4. Hospital Pharmacies
- 6.4.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
6.5. Retail Pharmacies
- 6.5.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
6.6. Others
- 6.6.1. Others Market, 2018 - 2030 (USD Million)

Chapter 7. Epithelioma Treatment Market: Regional Estimates & Trend Analysis

7.1. Regional Market Share Analysis, 2024 & 2030
7.2. Regional Market Dashboard
7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030
7.4. North America
- 7.4.1. North America Epithelioma Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
- 7.4.2. U.S.
  - 7.4.2.1. Key Country Dynamics
  - 7.4.2.2. Regulatory Framework
  - 7.4.2.3. Competitive Insights
  - 7.4.2.4. U.S. Epithelioma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.4.3. Canada
  - 7.4.3.1. Key Country Dynamics
  - 7.4.3.2. Regulatory Framework
  - 7.4.3.3. Competitive Insights
  - 7.4.3.4. Canada Epithelioma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.4.4. Mexico
  - 7.4.4.1. Key Country Dynamics
  - 7.4.4.2. Regulatory Framework
  - 7.4.4.3. Competitive Insights
  - 7.4.4.4. Mexico Epithelioma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.5. Europe
- 7.5.1. Europe Epithelioma Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
- 7.5.2. UK
  - 7.5.2.1. Key Country Dynamics
  - 7.5.2.2. Regulatory Framework
  - 7.5.2.3. Competitive Insights
  - 7.5.2.4. UK Epithelioma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.5.3. Germany
  - 7.5.3.1. Key Country Dynamics
  - 7.5.3.2. Regulatory Framework
  - 7.5.3.3. Competitive Insights
  - 7.5.3.4. Germany Epithelioma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.5.4. France
  - 7.5.4.1. Key Country Dynamics
  - 7.5.4.2. Regulatory Framework
  - 7.5.4.3. Competitive Insights
  - 7.5.4.4. France Epithelioma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.5.5. Italy
  - 7.5.5.1. Key Country Dynamics
  - 7.5.5.2. Regulatory Framework
  - 7.5.5.3. Competitive Insights
  - 7.5.5.4. Italy Epithelioma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.5.6. Spain
  - 7.5.6.1. Key Country Dynamics
  - 7.5.6.2. Regulatory Framework
  - 7.5.6.3. Competitive Insights
  - 7.5.6.4. Spain Epithelioma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.5.7. Norway
  - 7.5.7.1. Key Country Dynamics
  - 7.5.7.2. Regulatory Framework
  - 7.5.7.3. Competitive Insights
  - 7.5.7.4. Norway Epithelioma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.5.8. Denmark
  - 7.5.8.1. Key Country Dynamics
  - 7.5.8.2. Regulatory Framework
  - 7.5.8.3. Competitive Insights
  - 7.5.8.4. Denmark Epithelioma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.5.9. Sweden
  - 7.5.9.1. Key Country Dynamics
  - 7.5.9.2. Regulatory Framework
  - 7.5.9.3. Competitive Insights
  - 7.5.9.4. Sweden Epithelioma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.6. Asia Pacific
- 7.6.1. Asia Pacific Epithelioma Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
- 7.6.2. Japan
  - 7.6.2.1. Key Country Dynamics
  - 7.6.2.2. Regulatory Framework
  - 7.6.2.3. Competitive Insights
  - 7.6.2.4. Japan Epithelioma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.6.3. China
  - 7.6.3.1. Key Country Dynamics
  - 7.6.3.2. Regulatory Framework
  - 7.6.3.3. Competitive Insights
  - 7.6.3.4. China Epithelioma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.6.4. India
  - 7.6.4.1. Key Country Dynamics
  - 7.6.4.2. Regulatory Framework
  - 7.6.4.3. Competitive Insights
  - 7.6.4.4. India Epithelioma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.6.5. South Korea
  - 7.6.5.1. Key Country Dynamics
  - 7.6.5.2. Regulatory Framework
  - 7.6.5.3. Competitive Insights
  - 7.6.5.4. South Korea Epithelioma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.6.6. Australia
  - 7.6.6.1. Key Country Dynamics
  - 7.6.6.2. Regulatory Framework
  - 7.6.6.3. Competitive Insights
  - 7.6.6.4. Australia Epithelioma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.6.7. Thailand
  - 7.6.7.1. Key Country Dynamics
  - 7.6.7.2. Regulatory Framework
  - 7.6.7.3. Competitive Insights
  - 7.6.7.4. Thailand Epithelioma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.7. Latin America
- 7.7.1. Latin America Epithelioma Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
- 7.7.2. Brazil
  - 7.7.2.1. Key Country Dynamics
  - 7.7.2.2. Regulatory Framework
  - 7.7.2.3. Competitive Insights
  - 7.7.2.4. Brazil Epithelioma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.7.3. Argentina
  - 7.7.3.1. Key Country Dynamics
  - 7.7.3.2. Regulatory Framework
  - 7.7.3.3. Competitive Insights
  - 7.7.3.4. Argentina Epithelioma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.8. MEA
- 7.8.1. MEA Epithelioma Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
- 7.8.2. South Africa
  - 7.8.2.1. Key Country Dynamics
  - 7.8.2.2. Regulatory Framework
  - 7.8.2.3. Competitive Insights
  - 7.8.2.4. South Africa Epithelioma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.8.3. Saudi Arabia
  - 7.8.3.1. Key Country Dynamics
  - 7.8.3.2. Regulatory Framework
  - 7.8.3.3. Competitive Insights
  - 7.8.3.4. Saudi Arabia Epithelioma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.8.4. UAE
  - 7.8.4.1. Key Country Dynamics
  - 7.8.4.2. Regulatory Framework
  - 7.8.4.3. Competitive Insights
  - 7.8.4.4. UAE Epithelioma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.8.5. Kuwait
  - 7.8.5.1. Key Country Dynamics
  - 7.8.5.2. Regulatory Framework
  - 7.8.5.3. Competitive Insights
  - 7.8.5.4. Kuwait Epithelioma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

8.1. Participant Overview
8.2. Company Market Position Analysis
8.3. Company Categorization
8.4. Strategy Mapping
8.5. Company Profiles/Listing
- 8.5.1. Bristol-Myers Squibb Company
  - 8.5.1.1. Overview
  - 8.5.1.2. Financial Performance
  - 8.5.1.3. Product Benchmarking
  - 8.5.1.4. Strategic Initiatives
- 8.5.2. Merck & Co., Inc.
  - 8.5.2.1. Overview
  - 8.5.2.2. Financial Performance
  - 8.5.2.3. Product Benchmarking
  - 8.5.2.4. Strategic Initiatives
- 8.5.3. Novartis AG
  - 8.5.3.1. Overview
  - 8.5.3.2. Financial Performance
  - 8.5.3.3. Product Benchmarking
  - 8.5.3.4. Strategic Initiatives
- 8.5.4. Amgen Inc.
  - 8.5.4.1. Overview
  - 8.5.4.2. Financial Performance
  - 8.5.4.3. Product Benchmarking
  - 8.5.4.4. Strategic Initiatives
- 8.5.5. Pfizer Inc.
  - 8.5.5.1. Overview
  - 8.5.5.2. Financial Performance
  - 8.5.5.3. Product Benchmarking
  - 8.5.5.4. Strategic Initiatives
- 8.5.6. Sanofi
  - 8.5.6.1. Overview
  - 8.5.6.2. Financial Performance
  - 8.5.6.3. Product Benchmarking
  - 8.5.6.4. Strategic Initiatives
- 8.5.7. Johnson & Johnson Services, Inc.
  - 8.5.7.1. Overview
  - 8.5.7.2. Financial Performance
  - 8.5.7.3. Product Benchmarking
  - 8.5.7.4. Strategic Initiatives
- 8.5.8. F. Hoffmann-La Roche Ltd
  - 8.5.8.1. Overview
  - 8.5.8.2. Financial Performance
  - 8.5.8.3. Product Benchmarking
  - 8.5.8.4. Strategic Initiatives

상피종 치료제 시장 규모, 점유율, 동향 분석 보고서 : 종류별, 약물 종류별, 유통 채널별, 지역별, 부문별 예측(2025-2030년)

Epithelioma Treatment Market Size, Share & Trends Analysis Report By Type, By Drug Class (Hedgehog Pathway Inhibitors, Immune Checkpoint Inhibitors), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

상피종 치료제 시장 성장과 동향:

상피종 치료제 시장 : 분석 개요

목차

제1장 분석 방법·범위

제2장 주요 요약

제3장 상피종 치료제 시장 : 변수, 동향, 범위

제4장 상피종 치료제 시장 : 종류별 비즈니스 분석

제5장 상피종 치료제 시장 : 약물 종류별 비즈니스 분석

제6장 상피종 치료제 시장 : 유통 채널별 비즈니스 분석

제7장 상피종 치료제 시장 : 지역별 추정·동향 분석